Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €1.44 EUR
Change Today +0.008 / 0.56%
Volume 0.0
AQL On Other Exchanges
As of 6:48 AM 07/6/15 All times are local (Market data is delayed by at least 15 minutes).

arqule inc (AQL) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/11/15 - €2.32
52 Week Low
10/24/14 - €0.80
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ARQULE INC (AQL)

arqule inc (AQL) Related Businessweek News

No Related Businessweek News Found

arqule inc (AQL) Details

ArQule, Inc., a clinical-stage biotechnology company, researches and develops therapeutics for the treatment of cancer and rare diseases. Its lead product candidate is tivantinib, a small molecule inhibitor of the c-Met receptor tyrosine kinase and its biological pathway, which is in Phase III clinical trial for the treatment of liver cancer and non-small cell lung cancer; Phase II clinical trial for the treatment of mesothelioma and kidney cancer; and Phase I clinical trial for the treatment of pediatric tumors, as well as has completed Phase II clinical trial for the treatment of colorectal cancer. The company’s early clinical-stage products in Phase Ib clinical trials include ARQ 092, an inhibitor of the AKT serine/threonine kinase; ARQ 087, a multi-kinase inhibitor of the fibroblast growth factor receptor (FGFR) family for patients with cholangiocarcinoma and adrenocortical tumors, as well as with FGFR translocations, amplification, and mutations; and ARQ 761, an intravenously administered analogue of Beta-lapachone, which is used as a promoter of NQ01-mediated programmed cancer cell necrosis. Its pre-clinical development program also includes ARQ 751, a next-generation inhibitor of AKT. ArQule, Inc. has partnership agreement with Daiichi Sankyo Co., Ltd. to conduct research, clinical trials, and the commercialization of tivantinib for human cancer indications in the United States, Europe, South America, and internationally; and Kyowa Hakko Kirin Co., Ltd. to develop and commercialize tivantinib in Japan and parts of Asia. The company has collaboration agreement with the National Human Genome Research Institute of the NIH for a clinical trial investigating on ARQ 092, which is used for the treatment of Proteus syndrome. ArQule, Inc. was founded in 1993 and is headquartered in Burlington, Massachusetts.

40 Employees
Last Reported Date: 05/6/15
Founded in 1993

arqule inc (AQL) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $489.3K
President, Chief Operating Officer, General C...
Total Annual Compensation: $413.9K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $394.6K
Compensation as of Fiscal Year 2014.

arqule inc (AQL) Key Developments

ArQule Inc. Appoints Robert J. Weiskopf as Chief Financial Officer

ArQule Inc. announced that Robert J. Weiskopf has been appointed chief financial officer. Mr. Weiskopf was previously vice president of finance, corporate controller and treasurer of the company. He will retain the title of treasurer and continue to report to Paolo Pucci, chief executive officer of the company. Prior to joining the company in 2007, Mr. Weiskopf was chief financial officer of Aware Inc. from 2004 until 2006. Prior to that, Mr. Weiskopf was director of finance at Lightbridge Inc. from 2000 to 2004.

ArQule Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 10:30 AM

ArQule Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 10:30 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States.

ArQule Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

ArQule Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, research and development revenue was $2.785 million against $2.676 million a year ago. Loss from operations was $4.815785 million against $7.305 million a year ago. Net loss was $4.551 million or $0.07 per basic and diluted share against $7.141 million or $0.11 per basic and diluted share a year ago. The revenue increase is primarily due to lower contra-revenue from Daiichi Sankyo tivantinib program.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AQL:GR €1.44 EUR +0.008

AQL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AVEO Pharmaceuticals Inc $1.73 USD +0.01
CrystalGenomics Inc 21,100 KRW +900.00
Curis Inc $3.18 USD -0.10
Cytokinetics Inc $6.35 USD -0.17
Rigel Pharmaceuticals Inc $3.05 USD -0.09
View Industry Companies

Industry Analysis


Industry Average

Valuation AQL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.9x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ARQULE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at